- [IMMUNOLOGY AND IMMUNOTHERAPY]
- [CYTOKINE-BASED THERAPEUTICS]
- [IMMUNOMODULATION AND TUMOR MICROENVIRONMENT]
Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-α
Marcos Vasquez, Marta Consuegra-Fernández, Fernando Aranda, Aitor Jimenez, Shirley Tenesaca, Myriam Fernandez-Sendin, Celia Gomar, Nuria Ardaiz, Claudia Augusta Di Trani, Noelia Casares, Juan Jose Lasarte, Francisco Lozano, Pedro Berraondo
Multiple sclerosis (MS) is a chronic autoimmune disease with no curative treatment. The immune regulatory properties of type I IFNs have led to the approval of IFN-β for the treatment of relapsing-remitting MS. However, there is still an unmet need to improve the tolerability and efficacy of this therapy. In this work, we evaluated the sustained delivery of IFN-α1, either alone or fused to apolipoprotein A-1 by means of an adeno-associated viral (AAV) system in the mouse model of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis.
These in vivo experiments demonstrated the prophylactic and therapeutic efficacy of the AAV-IFN-α or AAV-IFN-α fused to apolipoprotein A-1 vectors in experimental autoimmune encephalomyelitis, even at low doses devoid of hematological or neurologic toxicity. The sustained delivery of such low-dose IFN-α resulted in immunomodulatory effects, consisting of proinflammatory monocyte and T regulatory cell expansion.
Moreover, encephalitogenic T lymphocytes from IFN-α-treated mice re-exposed to the myelin oligodendrocyte glycoprotein peptide in vitro showed a reduced proliferative response and cytokine (IL-17A and IFN-γ) production, in addition to upregulation of immunosuppressive molecules, such as IL-10, IDO, or PD-1. In conclusion, the results of the present work support the potential of sustained delivery of low-dose IFN-α for the treatment of MS and likely other T cell-dependent chronic autoimmune disorders.
CITATION J Immunol. 2019 Aug 1;203(3):696-704. doi: 10.4049/jimmunol.1801462. Epub 2019 Jun 17.